Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872

Planting, A. S. T.; Ardizzoni, Andrea; Vila, Jordi; Giaccone, Giuseppe; Scagliotti, Giorgio V.; Splinter, Ted A.W.; Kirkpatrick, A.; Dalesio, O.; McVie, J.G.

doi:10.1007/bf00689706

Cited by 6 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years chemotherapy, especially for nonsmall cell carcinoma of the lung, has become much more intense, leading to prolonged myelosuppression and thrombocytopenia. [32][33][34][35][36][37][38] In fact, one drug, hexamethylene bisacetamide, had as its major toxic side effect thrombocytopenia. Young et al 39 showed that of 33 patients receiving 10 day intravenous courses of the drug, four had bleeding.…”

Section: Thrombocytopeniamentioning

confidence: 99%

Use of Platelets and Other Transfusion Products in Patients with Malignancy

Bayer¹,

Bodensteiner²,

Tilzer³

et al. 1992

Semin Thromb Hemost

View full text Add to dashboard Cite

The need for blood components for oncology patients is small compared with the need for patients with hematologic malignancies. Appropriate use of blood components is necessary, not only medically, but also because of limited supply and availability. Agreement on when to use components is extremely important. In fact, at the time of this writing, the Transfusion Practices Committee of the AABB is conducting an extensive survey on the use of platelets in the oncology and hematology cancer patients (Questionnaire on Institutional Policy on Platelet Transfusion Practice for Hematology/Oncology Patients). The results will, it is hoped, provide a consensus on the proper times and counts that require prophylactic use of components for these patients. Since these patients use the vast majority of components (see Table 15), their proper use is imperative to maintaining an adequate platelet and frozen plasma supply. Transfusion support in cancer patients is vital for their survival. Platelets, in particular, are necessary to prevent serious bleeding. However, refractoriness to platelet transfusions can develop. It must be appreciated that refractoriness is not a general problem and need not require the expensiveness of a universal decision for handling all platelet transfusions in the same manner. Total refractoriness probably occurs in 15 to 20% of patients frequently transfused. In patients in whom frequent platelet transfusion is anticipated, that is, bone marrow transplantation, the development of platelet refractoriness may be reduced by using SDPC and administering them through leukocyte filters. Patients who become refractory to either random or SDPC can either be cross-matched for single-donor platelets that are compatible or can be given HLA-A,B matched platelets. Certainly, the success of platelet transfusion in leukemic patients cannot be denied, since only a small number of these patients now die because of bleeding due to platelet refractoriness. Most of the serious bleeding still seen is associated with sepsis. The risks from transfusion must always be considered. Fortunately, with increased monitoring of the blood supply, they have been reduced. As with any therapeutic regimen, these risks must be weighed against the benefit the patient may gain. Transfusion should always be used prudently.

show abstract

Section: Thrombocytopeniamentioning

confidence: 99%

Use of Platelets and Other Transfusion Products in Patients with Malignancy

Bayer¹,

Bodensteiner²,

Tilzer³

et al. 1992

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…8 This is the major reason why ACNU is preferred in Japan and in some European countries. In vitro experiments tend to explain this difference by illustrating the different selectivity of the various CENUs toward O6-methylguanine-DNA methyltransferase (MGMT)-expressing cells.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy for glioblastoma

Linz

2008

Cancer

View full text Add to dashboard Cite

show abstract

Phase II study of ACNU as second-line treatment in small-cell lung cancer

Planting

Splinter

Ardizzoni

et al. 1992

Cancer Chemother. Pharmacol.

View full text Add to dashboard Cite

A total of 24 patients presenting with small-cell lung cancer either resistant to or relapsing within 3 months after first-line treatment were entered in a phase II study of 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-(2-chloroethyl)-3- nitrosourea hydrochloride (ACNU). ACNU was given i.v. at a dose of 75 mg/m2 every 6 weeks. We observed a partial response of 7 months' duration in one patient and one case of stable disease that lasted for 6 months; all other subjects exhibited progressive disease. Two patients developed brain metastases during treatment. The toxicity of ACNU consisted mainly of bone marrow suppression, especially thrombocytopenia. At this dose and on this schedule, ACNU shows minimal activity as second-line treatment in small-cell lung cancer.

show abstract

Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872

Cited by 6 publications

References 3 publications

Use of Platelets and Other Transfusion Products in Patients with Malignancy

Use of Platelets and Other Transfusion Products in Patients with Malignancy

Chemotherapy for glioblastoma

Phase II study of ACNU as second-line treatment in small-cell lung cancer

Contact Info

Product

Resources

About